Verastem Names Michael P. Bailey CEO, Succeeding Dan Paterson in 2027
Tom Rudovsky · Reported by Wiseek News
More coverage: Biotech Stocks · Healthcare
Sentiment
Neutral
Importance
7
Price
$8.888
Mkt Cap
$674.698M
52W Low
--
52W High
--
52W Position
Off High
Rel. Volume
Market data snapshot near publication time
Summary
Verastem appointed Michael P. Bailey as President and CEO effective January 1, 2027. Current CEO Dan Paterson will retire from the role but remain on the board and as an advisor. Bailey has been on the board since May 2026, which should ease the transition. The change comes as the company commercializes AVMAPKI FAKZYNJA and advances VS-7375 in Phase 2 trials. Leadership continuity and strategic direction under Bailey will be key for the 2027 outlook.
At the time of this announcement, VSTM was trading at $8.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $674.7M. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.
Price Chart
VSTM - Latest Insights
VSTM
Oct 14, 2026, 5:18 PM EDT
Price at Filing:
$7.92
Real-time Price:
$9.74
Change:
+$1.82 (+23%)
Market Cap:
$1.183B
VSTM
Oct 14, 2026, 5:14 PM EDT
Price at Filing:
$7.92
Real-time Price:
$9.74
Change:
+$1.82 (+23%)
Market Cap:
$1.183B
VSTM
Oct 14, 2026, 6:08 AM EDT
Price at Filing:
$8.79
Real-time Price:
$9.74
Change:
+$0.950 (+11%)
Market Cap:
$1.183B
VSTM
Oct 14, 2026, 6:04 AM EDT
Price at Filing:
$7.53
Real-time Price:
$9.74
Change:
+$2.21 (+29%)
Market Cap:
$1.183B
VSTM
Oct 14, 2026, 6:00 AM EDT
Price at Filing:
$8.89
Real-time Price:
$9.74
Change:
+$0.8517 (+10%)
Market Cap:
$1.183B